Mumbai (Maharashtra) [India], July 13 (ANI): Glenmark Pharmaceuticals said on Monday it has cut the price of its anti-viral drug Favipiravir under the brand name FabiFlu for treatment of patients with mild to moderate COVID-19 by 27 per cent to Rs 75 per tablet.
New Delhi [India], June 20 (ANI): Domestic pharmaceuticals Glenmark on Saturday informed that their antiviral drug -- Favipiravir -- has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases, including those with co-morbidities.
New Delhi [India], June 19 (ANI): The Drug Controller General of India (DCGI) has granted permission to anti-viral drug favipiravir for "restricted emergency use" in mild to moderate cases of COVID-19, a senior government official confirmed to ANI.